Proactive Research analyst Emma Ulker says Open Orphan PLC's (LON:ORPH) full year 2019 results reflect a period of transition, as the company consolidated only six months of Venn revenues, with the focus being on integration and ongoing streamlining of the business, following the post–period acquisition of hVIVO in January.
Ulker says the outlook includes expanding its range of pharma services and completing the development of a COVID-19 HVC model which is already attracting the attention of the global pharma industry.